How LRP5 and LRP6 control bone strength and metabolism
Lrp5 and Lrp6 signaling in bone mechanotransduction and metabolism
This work looks at how two related proteins, LRP5 and LRP6, help bones respond to physical loading so treatments can make bones stronger without hurting the heart.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11197606 on NIH RePORTER |
What this research studies
If you have osteoporosis or worry about fractures, this research studies two proteins (LRP5 and LRP6) that help bone sense mechanical load. Researchers will use laboratory experiments, animal and tissue models, and molecular techniques to compare how each protein affects bone formation and cardiovascular tissues. The team aims to separate the bone-building effects from the heart-related side effects seen with some WNT-targeting drugs. Findings could guide therapies that work with exercise to direct new bone where it is most needed while reducing cardiovascular risk.
Who could benefit from this research
Good fit: People with osteoporosis or at high risk of fracture, especially those concerned about cardiovascular risks from current WNT-targeting treatments, would be most relevant to this research.
Not a fit: Patients whose bone problems are caused by conditions unrelated to WNT/LRP signaling (for example certain cancers or non-WNT genetic disorders) may not benefit from these findings.
Why it matters
Potential benefit: Could lead to safer osteoporosis therapies that strengthen bone with fewer cardiovascular side effects.
How similar studies have performed: Drugs targeting the WNT pathway (for example romosozumab) have shown strong bone-building effects but raised cardiovascular safety concerns, and separating LRP5 versus LRP6 roles is a newer, less-tested approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Robling, Alexander G — Indiana University Indianapolis
- Study coordinator: Robling, Alexander G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.